MedTrace Logo

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants

NCT03390647 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-07-31

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of E6130 in Japanese healthy adult male participants.

Conditions

  • Healthy Participants

Interventions

DRUG

E6130

Oral dose

DRUG

Placebo

E6130-matched placebo

Sponsors & Collaborators

  • EA Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
44 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-21
Primary Completion
2019-03-31
Completion
2019-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03390647 on ClinicalTrials.gov